Latest News for 07/2022
17 May 2022
Professor Alessio Ciulli has been awarded a European Federation for Medicinal Chemistry and Chemical Biology Awards 2022. He has been named the winner of the 2022 Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery. This award has been in recognition of his “pioneering work in the field of proteolysis-targeting chimera (PROTAC) technology for drug-induced targeted protein degradation.
04 May 2022
University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion. As part of separate partnerships, Amphista will collaborate with Merck Healthcare and Bristol Myers Squibb to leverage the company’s targeted protein degradation (TPD) technology and generate therapeutics in multiple disease areas.
03 May 2022
Dr Xingui Liu has been awarded a Marie Skłodowska-Curie Fellowship to undertake research in the lab of Professor Alessio Ciulli in the newly established Centre for Targeted Protein Degradation (CeTPD). The project is in collaboration with Professor Dario Alessi from the MRC Protein Phosphorylation and Ubiquitylation Unit and a Japanese pharmaceutical company.
10 Mar 2022
A research publication by Tasuku Ishida and Alessio Ciulli has been named one of the 2021 SLAS Readers Choice Award winners. The annual awards from the Society for Laboratory Automation and Screening (SLAS) honour articles and authors from 2021 published editions of SLAS Discovery and SLAS Technology.
18 Jan 2022
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding. The annual Scrips Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. The awards span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and fundraising.
21 Oct 2021
Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in a field of chemical biology that is revolutionising drug discovery. Targeted protein degradation co-opts the cell’s natural disposal systems to remove disease-causing proteins and is applicable to diverse therapeutic areas including oncology, inflammation, dermatology, immunology and respiratory diseases.
19 Oct 2021
Scientists at the University of Dundee have developed a new technology that provides a greater understanding into the biology of ‘undruggable’ diseases. Cells are composed of thousands of interacting proteins and their malfunction is a primary mechanism of disease development. Drug discovery scientists’ goal is to identify these aberrant proteins, understand their function and develop novel compounds to target them.
08 Oct 2021
The University of Dundee is one of the best universities in the UK for producing successful spinouts, according to a new report. The University Spinout Report 2021, carried out by GovGrant, names Dundee as the UK's sixth most successful at commercialising innovation. The University spawned 1.5% of the UK’s spinouts with these companies raising £325.7 million over the past two decades.
19 Jul 2021
The expansion of an exemplary industry-academia collaboration will see the University of Dundee, in partnership with Boehringer Ingelheim, intensify its efforts to develop new medicines that target and destroy key cancer-causing proteins, which have previously been regarded as undruggable.
14 Apr 2021
A new translational research centre will bolster the University of Dundee’s world-leading position in a field of chemical biology that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.